Home/Filings/4/0001910662-25-000003
4//SEC Filing

LaBrosse Nicole 4

Accession 0001910662-25-000003

CIK 0001159036other

Filed

Sep 22, 8:00 PM ET

Accepted

Sep 23, 4:15 PM ET

Size

7.4 KB

Accession

0001910662-25-000003

Insider Transaction Report

Form 4
Period: 2025-09-22
LaBrosse Nicole
SVP, CHIEF FINANCIAL OFFICER
Transactions
  • Sale

    Common Stock

    2025-09-22$77.83/sh1,913$148,88322,393 total
  • Sale

    Common Stock

    2025-09-22$78.67/sh314$24,70122,079 total
Footnotes (3)
  • [F1]The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025.
  • [F2]Represents a weighted average sales price per share. These shares were sold at prices ranging from $77.34 to $78.32. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  • [F3]Represents a weighted average sales price per share. These shares were sold at prices ranging from $78.37 to $79.18. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Issuer

HALOZYME THERAPEUTICS, INC.

CIK 0001159036

Entity typeother

Related Parties

1
  • filerCIK 0001910662

Filing Metadata

Form type
4
Filed
Sep 22, 8:00 PM ET
Accepted
Sep 23, 4:15 PM ET
Size
7.4 KB